Log in Book a Demo

US Pharma & Biotech Cardiology - PPC Market Share Analysis April 2025

Leveraging Adthena’s Whole Market View, this analysis explores recent trends in Google Ads for the US Cardiology category from the last month. Our Data Analyst, Ask Arlo provides commentary on key findings.

Market Exposure

Share of Clicks for top 10 US Pharma & Biotech Cardiology brands

Here are the Top 10 competitors in the industry by Share of Clicks for the last month.

See more data
Share of Clicks - Last month
Domain Share of clicks
repatha.com 58.71
repathahcp.com 10.43
bioyouthlabs.com 2.52
veltassa.com 2.29
vyndamax.com 2.26
bmscustomerconnect.com 2.12
naomiw.com 1.89
ascension.org 1.8
1md.org 1.4
farxiga.com 1.37
others 15.21

Copyright © Adthena. All rights reserved.

Repatha.com dominates with 58.71% click share, overshadowing others at 15.21%. Repathahcp.com follows at 10.43%, while smaller players like farxiga.com hold 1.37%.

Market Exposure

Share of Spend for the top 10 US Pharma & Biotech Cardiology brands

Curious about your market position? Here you can see the Top 10 competitors in the industry by Share of Spend for the last month. 

See more data
Share of Spend - Last Month
Date repatha.com veltassa.com vyndamax.com repathahcp.com bmscustomerconnect.com farxiga.com naomiw.com ascension.org bioyouthlabs.com thorne.com
2025/04/01 0.24% 23.37% 0% 0.04% 0% 0% 9.07% 2.02% 6.47% 10.36%
2025/04/02 7.45% 45.31% 0% 5.79% 0% 0% 9.41% 0% 3.39% 7%
2025/04/03 0.19% 39.19% 0% 0.04% 0% 0% 7.84% 1.54% 4.07% 7.03%
2025/04/04 48.11% 10.18% 1.14% 18.07% 1.4% 0% 4.04% 0.21% 1.3% 2.15%
2025/04/05 72.8% 0% 0.18% 15.19% 0% 0% 1.85% 0.64% 0.57% 1.86%
2025/04/06 68.09% 0% 0.25% 18.4% 0.9% 0% 0.97% 0% 0.33% 0.47%
2025/04/07 53.77% 0% 0% 13.15% 4.16% 0% 1.06% 11.43% 0.38% 1.37%
2025/04/08 63.92% 0% 3.33% 18.07% 0.16% 0% 0.47% 1.2% 0% 1.46%
2025/04/09 65.28% 0% 0.98% 14.3% 0.04% 0% 0.71% 0% 0.51% 0.69%
2025/04/10 66.78% 0% 2.92% 10.69% 2% 0% 1.99% 0% 0.83% 0.87%
2025/04/11 62.2% 0% 1.54% 16.17% 0.81% 0% 1.13% 8.38% 0.43% 0.98%
2025/04/12 63.08% 0% 2.73% 20.49% 1.88% 0% 1.26% 0% 0.69% 1.58%
2025/04/13 62.07% 0% 2.56% 16.04% 2.11% 0% 1.92% 0.84% 1.5% 0.23%
2025/04/14 54.53% 0% 1.2% 18.29% 2.13% 0% 0.84% 0% 4.32% 0.23%
2025/04/15 61.96% 0% 6.29% 3.93% 0.07% 3.27% 1.57% 0% 5.73% 1.11%
2025/04/16 44.3% 0% 2.89% 16.3% 0.17% 0% 3.64% 2.6% 3.23% 1.79%
2025/04/17 70.1% 0% 2.56% 8.77% 0.09% 4.3% 0.83% 1.53% 2.01% 0%
2025/04/18 73.53% 0% 1.57% 9.38% 0.01% 5.72% 0.2% 0% 1.91% 0.43%
2025/04/19 76.07% 0% 1.22% 13.89% 0.02% 0.69% 0% 0% 0% 0%
2025/04/20 69.04% 0% 1.42% 20.82% 0.69% 0.02% 0.28% 0% 0.12% 0%
2025/04/21 55.64% 0% 6.32% 12.98% 0.19% 4.23% 0.6% 1.28% 0% 0%
2025/04/22 60.42% 0% 7.45% 13.57% 0% 2.04% 1.22% 0% 0.33% 0.94%
2025/04/23 75.99% 0% 2.62% 13.29% 0% 0.05% 0.41% 0% 0.49% 0%
2025/04/24 66.75% 0% 8.39% 10.43% 0% 0.07% 1.71% 0% 0% 0%
2025/04/25 57.13% 0% 15.86% 4.58% 10.53% 0.11% 0.88% 0% 0% 0%
2025/04/26 45.37% 0% 12.62% 13.41% 10.73% 0.01% 2.18% 0.94% 0.65% 0.54%
2025/04/27 47.31% 0% 13.48% 11.06% 4.86% 7.76% 1.61% 0% 0% 0%
2025/04/28 36.33% 0% 15.36% 15.57% 7.6% 0.02% 0% 0% 0% 0%
2025/04/29 56.16% 4.01% 12.89% 10.41% 2.66% 0.08% 0% 0% 0% 0%
2025/04/30 53.38% 13.87% 10.73% 8.37% 6.31% 0.3% 0% 0% 0% 0%

Copyright © Adthena. All rights reserved.

Repatha.com dominated April’s PPC landscape, peaking at 76.07% on April 19. Veltassa.com and Vyndamax.com showed fluctuating trends, while Repathahcp.com maintained moderate activity. Farxiga.com spiked on April 27.

Market Exposure

Competitor Count for US Pharma & Biotech Cardiology

Ever wondered how many competitors you’re up against in your industry? Well look no further, here we can see the number of advertisers bidding over the last month. 

See more data
Competitor Count - Last month
Date Competitor Count
2025/04/01 34
2025/04/02 27
2025/04/03 33
2025/04/04 38
2025/04/05 36
2025/04/06 43
2025/04/07 39
2025/04/08 37
2025/04/09 34
2025/04/10 30
2025/04/11 32
2025/04/12 36
2025/04/13 40
2025/04/14 32
2025/04/15 35
2025/04/16 29
2025/04/17 44
2025/04/18 36
2025/04/19 29
2025/04/20 35
2025/04/21 28
2025/04/22 30
2025/04/23 28
2025/04/24 26
2025/04/25 19
2025/04/26 25
2025/04/27 19
2025/04/28 19
2025/04/29 21
2025/04/30 16

Copyright © Adthena. All rights reserved.

April began with 34 advertisers, peaking at 44 mid-month. A decline followed, ending with 16 advertisers.

Campaign Efficiency

Market Loss & Market Gains for US Pharma & Biotech Cardiology

Here we’re looking at the Top 10 biggest industry movers by market share gains and losses for the last 30 days.

See more data
Market Loss & Market Gains - Last month
Name Market Trend
repatha.com 6.21%
farxiga.com 2.49%
vyndamax.com 2.31%
farxiga-hcp.com 1.41%
nexlizethcp.com 1.32%
healthfitnesslongevity.com -1.3%
naomiw.com -1.44%
ascension.org -1.6%
repathahcp.com -1.65%
thorne.com -1.66%

Copyright © Adthena. All rights reserved.

Repatha.com surged with a 6.21% click share increase, while thorne.com dropped by 1.66%. Farxiga.com also rose by 2.49%, contrasting with repathahcp.com’s 1.65% decline.

Campaign Efficiency

US Pharma & Biotech Cardiology Share of Impressions

Take a look at the Top 10 competitors in the industry by Share of Impressions over the last month.

See more data
Date repatha.com repathahcp.com nexlizethcp.com farxiga.com naomiw.com pure-health-research.com 1md.org ascension.org bioyouthlabs.com thorne.com
2025/04/01 0.11% 0.02% 0% 0% 12.51% 3.14% 7.84% 1.56% 9.41% 14.08%
2025/04/02 2.34% 2.24% 0% 0% 18.28% 6.65% 8.32% 0% 6.66% 13.29%
2025/04/03 0.1% 0.02% 0% 0% 11.24% 5.62% 4.22% 1.81% 7.04% 11.24%
2025/04/04 24.22% 20.48% 0% 0% 9.83% 1.57% 2.36% 0.36% 4.19% 5.49%
2025/04/05 37.79% 22.81% 1.29% 0% 6.44% 2.58% 3.22% 2.27% 2.8% 7.09%
2025/04/06 40.93% 23.41% 0.66% 0% 2.6% 3.13% 2.6% 0.01% 1.52% 1.3%
2025/04/07 27.47% 14.98% 0.64% 0% 3.11% 2.49% 2.49% 15.45% 1.25% 3.73%
2025/04/08 40.02% 23.88% 1.13% 0% 1.31% 1.97% 3.29% 3.21% 0% 4.6%
2025/04/09 38.64% 16.91% 1.2% 0% 1.8% 2.4% 2.4% 0% 1.8% 2.4%
2025/04/10 42.36% 12.41% 0.93% 0% 5.6% 3.73% 4.67% 0% 2.8% 2.8%
2025/04/11 29.66% 18.77% 1.08% 0% 3.8% 1.63% 2.71% 13.46% 1.67% 3.25%
2025/04/12 33.92% 25.87% 0% 0% 4.36% 2.91% 2.91% 0% 2.91% 5.81%
2025/04/13 32.09% 19.18% 0.99% 0% 5.82% 2.91% 3.64% 2.62% 4.85% 0.73%
2025/04/14 22.76% 22.7% 2.2% 0% 1.89% 1.26% 2.52% 0% 12.16% 0.63%
2025/04/15 20.02% 4.2% 0% 8.87% 4.54% 1.81% 2.72% 0% 17.54% 3.63%
2025/04/16 14.59% 13.03% 0% 0% 7.08% 3.54% 7.21% 2.06% 9.44% 3.54%
2025/04/17 30.74% 13.81% 2.43% 8.33% 2.21% 0.88% 1.46% 6.35% 6.64% 0%
2025/04/18 43.58% 14.78% 0.25% 14.47% 0.75% 1.13% 1.13% 0% 6.89% 1.5%
2025/04/19 48.54% 21.25% 3.3% 2.96% 0% 0.85% 0% 0% 0% 0%
2025/04/20 42.32% 35.68% 2.21% 0.62% 1.28% 0.64% 0.64% 0% 0.85% 0%
2025/04/21 33.57% 15.25% 7.39% 8.98% 1.67% 1.67% 0.83% 2.04% 0% 0%
2025/04/22 38.39% 15.98% 3.68% 4.33% 3.61% 2.41% 2.41% 0% 1.2% 2.41%
2025/04/23 57% 18.94% 0.3% 0.16% 1.83% 1.83% 1.83% 0% 1.83% 0%
2025/04/24 45.19% 16.99% 3.72% 0.16% 5.53% 1.84% 3.69% 0% 0% 0%
2025/04/25 38.91% 6.88% 3.62% 0.31% 3.56% 0% 3.56% 0% 0% 0%
2025/04/26 26.59% 18.1% 1.82% 0.02% 7.02% 3.51% 3.51% 1.75% 1.75% 1.75%
2025/04/27 27.94% 12.02% 3.3% 16.67% 4.95% 2.47% 2.47% 0% 0% 0%
2025/04/28 28.95% 21.47% 13.13% 0.05% 0% 0% 0% 0% 0% 0%
2025/04/29 39.81% 15.51% 15.45% 0.35% 0% 0% 0% 0% 0% 0%
2025/04/30 35.83% 11.3% 4.85% 1.08% 0% 0% 0% 0% 0% 0%

Copyright © Adthena. All rights reserved.

Repatha.com dominated April’s PPC landscape, peaking at 57% on April 23. Repathahcp.com and naomiw.com followed, with notable fluctuations. By month’s end, Repatha.com maintained a strong presence, closing at 35.83%.

Campaign Efficiency

Google Text Ad Copy Insights & Creative Trends for US Pharma & Biotech Cardiology

Ever wondered how your rivals’ ads are doing? Here we can see the top-performing ads in the industry over the last month.

See more data
  1. 1
    A New Treatment Option - Turn Heart Failure To Success https://www.barostim.com

    Suffering From Symptoms of Heart Failure & Prescription Drugs Not Making You Feel Better?

  2. 2
    Free Heart Health Screening | No-cost screening https://cardiometabolicscreening.careaccess.com

    Proactive Heart Care, Begin with a Comprehensive Risk Evaluation

  3. 3
    A Treatment For Heart Failure - Pay As Little As $0 Per Month Prescription treatment website

    Learn About A Treatment That May Help Reduce The Risk Of Hospitalization For Heart Failure. Reduce The Risk Of Heart Failure Hospitalization & Cardiovascular Death With Just One Pill.

  4. 4
    Repatha® (evolocumab) - Visit the Official Website https://www.repatha.com/

    Visit the Official Patient Website for Information on Repatha® As a Treatment Option. Find Dosing Options and Treatment Information by...

  5. 5
    Repatha® (evolocumab) - Dosing & Administration https://www.repathahcp.com/

    Learn More About Repatha by Visiting the Official Product Website for Physicians. Explore HCP Resources and Learn More About...

Copyright © Adthena. All rights reserved.

In the competitive landscape of heart health, Barostim’s ad stands out by offering hope to those struggling with heart failure. CareAccess promotes proactive heart care with free screenings, while Farxiga emphasizes affordability and reduced hospitalization risks. Repatha targets both patients and physicians, providing comprehensive treatment information.

Frequently Asked Questions

Customer Success Stories

the7stars Case study: PPC campaign Optimization

the7stars case study: Achieving Google Ads PPC campaign optimization​ with Adthena

Leveraging Adthena's comprehensive insights, the7stars and their lottery client optimized their PPC campaigns and organic strategies, resulting in substantial cost savings and improved campaign performance. Read case study
Sage Case study: Brand protection strategy

Sage case study: 75% decrease in CPCs with Adthena

Sage, a leading UK software provider, used Adthena’s brand protection strategy to curb rising CPC costs. By identifying brand infringements and optimizing spend, they effectively strengthened their brand protection strategy and increased ROI.Read case study

Vodafone case study: Driving click share and sales with strategic insights from Adthena

Vodafone used Adthena data to optimize results from the launch of the Samsung S22 product. Combining Adthena’s Strategic Insights with Google Smart Bidding, Vodafone was able to maintain a flexible strategy that leveraged both manual and automated bidding. Leveraging Adthena’s Search Term Opportunities report also allowed Vodafone to implement 27 keyword terms across their business line, driving an increase in revenue at a positive ROAS.Read case study

Get the full picture

See this data specific to your brand performance

The data on this page is just a sample of the billions of data points we hold at Adthena. The insights generated by Ask Arlo, leverage real-time GenAI to answer questions about your search data.

Our search consultants can introduce you to Whole Market View data that is specific to your organization, based on the size of the relevant search term and competitor universe, and the locations that you need monitoring.

Related reports

US
Pharma & Biotech

US Pharmacology

US
Pharma & Biotech

US Research and Development

US
Pharma & Biotech

US Pulmonology

UK
Pharma & Biotech

UK Pharmacology